Hyaluronic Acid Viscosupplementation | Global | 2017 | Market Analysis
The global market for HA viscosupplementation will exhibit moderate growth through 2025, driven by rising use of this treatment, especially in the Asia Pacific region. While premium-priced 1-injection products will continue to become more popular over the forecast period, 3- and 5-injection products will retain their dominance in some countries due to differences in product access and reimbursement, and because there is more clinical data supporting the efficacy of these products.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for the US, Europe, Asia Pacific, and Brazil across a 10-year period.
The continuing introduction of products and expanded indications in the HA viscosupplementation market will drive market growth.
How will the introduction of new products help offset the negative recommendation against HA injections by the AAOS in the US?
How quickly will the nonknee market segment expand in the US following the anticipated approval of these indications?
Reimbursement for HA injections is facing greater scrutiny in Europe.
Which countries have limited or a complete lack of reimbursement for these products?
In France, what reimbursement changes have occurred and what decisions are still pending? What strategies can companies use to promote their products when reimbursement is lacking?
In the Asia Pacific region and Brazil, domestic manufacturers have gained market share.
How are domestic manufacturers’ product offerings evolving?
In which countries do domestic companies hold particularly high market shares and why?
